HTR4
ENSG00000164270
Target class
GPCR
Chromosome
5
Approved drugs
8
Clinical candidates (approved and in development)
20
- Approved drugs
- 8
- Clinical candidates (approved and in development)
- 20
- Chemical probe available
- Yes
- Other names
- 5-HT4
- Target name
- HTR4
- Gene name
- 5-hydroxytryptamine receptor 4
- Gene symbol
- HTR4
- Protein name
- 5-hydroxytryptamine receptor 4 (5-HT-4) (5-HT4) (Serotonin receptor 4)
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 3
- Highest tissue expression
- 2.34
- Tissue specificity (Gini)
- 0.73
- Tissue specificity (tau)
- 0.913
- KEGG gene identifiers
- hsa:3360
- Protein interaction confidence
- 0.891
- Protein interaction partners
- 4
- R-HSA-390666
- R-HSA-418555
- End position
- 148677235
- Start position
- 148446042
- Chromosome
- 5
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Endosome membrane
- Multi-pass membrane protein . Note=Interaction with SNX27 mediates recruitment to early endosomes, while interaction with NHERF1 and EZR might target the protein to specialized subcellular regions, such as microvilli. .
- PubMed 10821780
- PubMed 35714614
- Tissue specificity (tau)
- 0.913159
- Expression inequality (Gini)
- 0.729793
Expression in transcripts per million
- Small Intestine - Terminal Ileum
- 2.34
- Colon - Transverse
- 1.36
- Brain - Nucleus accumbens (basal ganglia)
- 1.24
- Pituitary
- 0.86
- Heart - Atrial Appendage
- 0.85
Expression in transcripts per million
- Small Intestine - Terminal Ileum2.34
- Colon - Transverse1.36
- Brain - Nucleus accumbens (basal ganglia)1.24
- Pituitary0.86
- Heart - Atrial Appendage0.85
- Artery - Aorta0.8
- Artery - Coronary0.79
- Brain - Caudate (basal ganglia)0.76
- Colon - Sigmoid0.73
- Artery - Tibial0.5
- Brain - Frontal Cortex (BA9)0.36
- Brain - Cortex0.35
- Brain - Putamen (basal ganglia)0.29
- Adrenal Gland0.2
- Brain - Anterior cingulate cortex (BA24)0.18
- Brain - Hippocampus0.16
- Heart - Left Ventricle0.1
- Fallopian Tube0.08
- Brain - Hypothalamus0.08
- Testis0.07
- Nerve - Tibial0.07
- Brain - Amygdala0.07
- Skin - Not Sun Exposed (Suprapubic)0.06
- Skin - Sun Exposed (Lower leg)0.06
- Uterus0.05
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007187
- GO:0007189
- GO:0007192
- GO:0120056
- GO:0005737
- GO:0005886
- GO:0016020
- GO:0004993
- GO:0005515
- GO:0099589
increased gastric emptying
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased gastric emptying
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264fainting
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: fainting
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264diarrhea
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: diarrhea
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased gastrointestinal transit
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased gastrointestinal transit
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart rate
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased blood volume
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood volume
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased anxiety
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased anxiety
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastrointestinal transit
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased gastrointestinal transit
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased memory
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased QTc interval
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased QTc interval
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264
Related records
Trials (367)
- "THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"
- A Clinical Study Assessing the Potential of Piboserod for the Treatment of Heart Failure
- A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes
- A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill Patients
- A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.
- A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.
- A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome
- A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation
- A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
- A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation
- A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents
- A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea And Vomiting in the Bariatric Surgery Population
- A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation
- A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance
- A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic Constipation
- A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
- A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults
- A Study of ANAVEX3-71 in Adults With Schizophrenia
- A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
Drugs (25)
- Amisulpride Serotonin (5-HT) receptor antagonist
- Capeserod Serotonin 4 (5-HT4) receptor partial agonist
- Cisapride Serotonin 4 (5-HT4) receptor agonist
- Cisapride monohydrate Serotonin 4 (5-HT4) receptor agonist
- Clebopride Serotonin 4 (5-HT4) receptor agonist
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Felcisetrag Serotonin 4 (5-HT4) receptor agonist
- Levosulpiride Serotonin 4 (5-HT4) receptor agonist
- Metoclopramide Serotonin 4 (5-HT4) receptor agonist
- Metoclopramide hydrochloride Serotonin 4 (5-HT4) receptor agonist
- Mosapride Serotonin 4 (5-HT4) receptor agonist
- Naronapride Serotonin 4 (5-HT4) receptor agonist
- Piboserod Serotonin 4 (5-HT4) receptor antagonist
- Prucalopride Serotonin 4 (5-HT4) receptor agonist
- Prucalopride succinate Serotonin 4 (5-HT4) receptor agonist
- PRX-03140 Serotonin 4 (5-HT4) receptor partial agonist
- Relenopride Serotonin 4 (5-HT4) receptor agonist
- Renzapride Serotonin 4 (5-HT4) receptor agonist
- Revexepride Serotonin 4 (5-HT4) receptor agonist